We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 01, 2021

Tirzepatide Improves Cardiovascular Risk Biomarkers in Patients With Type 2 Diabetes

Diabetes, Obesity & Metabolism


Additional Info

Diabetes, Obesity & Metabolism
The Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Biomarkers in Patients with Type 2 Diabetes: a Post-Hoc Analysis
Diabetes Obes Metab 2021 Sep 20;[EPub Ahead of Print], JM Wilson, Y Lin, MJ Luo, G Considine, AL Cox, LM Bowsman, DA Robins, A Haupt, KL Duffin, G Ruotolo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading